These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 19261873

  • 1. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.
    Kotermanski SE, Johnson JW.
    J Neurosci; 2009 Mar 04; 29(9):2774-9. PubMed ID: 19261873
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mechanism of action of memantine.
    Johnson JW, Kotermanski SE.
    Curr Opin Pharmacol; 2006 Feb 04; 6(1):61-7. PubMed ID: 16368266
    [Abstract] [Full Text] [Related]

  • 7. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA.
    Curr Alzheimer Res; 2005 Apr 04; 2(2):155-65. PubMed ID: 15974913
    [Abstract] [Full Text] [Related]

  • 8. Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes.
    Wrighton DC, Baker EJ, Chen PE, Wyllie DJ.
    J Physiol; 2008 Jan 01; 586(1):211-25. PubMed ID: 17962329
    [Abstract] [Full Text] [Related]

  • 9. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA, Wenk GL.
    CNS Drug Rev; 2003 Jan 01; 9(3):275-308. PubMed ID: 14530799
    [Abstract] [Full Text] [Related]

  • 10. Permeant ion effects on external Mg2+ block of NR1/2D NMDA receptors.
    Qian A, Johnson JW.
    J Neurosci; 2006 Oct 18; 26(42):10899-910. PubMed ID: 17050728
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA.
    J Alzheimers Dis; 2004 Dec 18; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels.
    Chen HS, Lipton SA.
    J Pharmacol Exp Ther; 2005 Sep 18; 314(3):961-71. PubMed ID: 15901795
    [Abstract] [Full Text] [Related]

  • 14. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
    Kleckner NW, Glazewski JC, Chen CC, Moscrip TD.
    J Pharmacol Exp Ther; 1999 May 18; 289(2):886-94. PubMed ID: 10215667
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.
    Gideons ES, Kavalali ET, Monteggia LM.
    Proc Natl Acad Sci U S A; 2014 Jun 10; 111(23):8649-54. PubMed ID: 24912158
    [Abstract] [Full Text] [Related]

  • 16. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
    Gilling KE, Jatzke C, Hechenberger M, Parsons CG.
    Neuropharmacology; 2009 Apr 10; 56(5):866-75. PubMed ID: 19371579
    [Abstract] [Full Text] [Related]

  • 17. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X.
    Curr Alzheimer Res; 2012 Jul 10; 9(6):746-58. PubMed ID: 21875407
    [Abstract] [Full Text] [Related]

  • 18. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
    Kato T.
    Nihon Yakurigaku Zasshi; 2004 Sep 10; 124(3):145-51. PubMed ID: 15333987
    [Abstract] [Full Text] [Related]

  • 19. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS, Lipton SA.
    J Neurochem; 2006 Jun 10; 97(6):1611-26. PubMed ID: 16805772
    [Abstract] [Full Text] [Related]

  • 20. Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition.
    Misiachna A, Konecny J, Kolcheva M, Ladislav M, Prchal L, Netolicky J, Kortus S, Zahumenska P, Langore E, Novak M, Hemelikova K, Hermanova Z, Hrochova M, Pelikanova A, Odvarkova J, Pejchal J, Kassa J, Zdarova Karasova J, Korabecny J, Soukup O, Horak M.
    Biomed Pharmacother; 2024 Sep 10; 178():117201. PubMed ID: 39053419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.